| Market Cap | 213.09M | P/E | - | EPS this Y | 75.50% | Ern Qtrly Grth | - |
| Income | -338.04M | Forward P/E | -1.07 | EPS next Y | 43.60% | 50D Avg Chg | -16.00% |
| Sales | 126.52M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 3.00 | Quick Ratio | 0.20 | Shares Outstanding | 161.02M | 52W Low Chg | 10.00% |
| Insider Own | 55.41% | ROA | -28.04% | Shares Float | 64.02M | Beta | 1.71 |
| Inst Own | 25.27% | ROE | - | Shares Shorted/Prior | 1.43M/3.50M | Price | 0.36 |
| Gross Margin | -3.73% | Profit Margin | -267.19% | Avg. Volume | 618,227 | Target Price | 0.65 |
| Oper. Margin | -231.44% | Earnings Date | - | Volume | 86,736 | Change | -1.58% |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
| Raymond James | Outperform | Aug 28, 23 |
| Ladenburg Thalmann | Buy | May 17, 23 |
| Goldman Sachs | Neutral | May 17, 23 |
| Raymond James | Outperform | May 17, 23 |
| Raymond James | Outperform | Apr 10, 23 |
| Raymond James | Outperform | Apr 7, 23 |
| Goldman Sachs | Neutral | Mar 22, 23 |
| Raymond James | Outperform | Mar 22, 23 |
| Raymond James | Outperform | Nov 11, 22 |